Therapeutic Human Papillomavirus Vaccines: Current Clinical Trials and Future Directions

Overview

Journal Expert Opin Biol Ther

Specialties Biology
Pharmacology

Date 2008 Mar 21

PMID 18352847

Citations 67

Authors

Chien-Fu Hung

Barbara Ma

Archana Monie

Shaw-Wei Tsen

T-C Wu

Affiliations

Soon will be listed here.

Abstract

Background: Cervical cancer is the second largest cause of cancer deaths in women worldwide. It is now evident that persistent infection with high-risk human papillomavirus (HPV) is necessary for the development and maintenance of cervical cancer. Thus, effective vaccination against HPV represents an opportunity to restrain cervical cancer and other important cancers. The FDA recently approved the HPV vaccine Gardasil for the preventive control of HPV, using HPV virus-like particles (VLP) to generate neutralizing antibodies against major capsid protein, L1. However, prophylactic HPV vaccines do not have therapeutic effects against pre-existing HPV infections and HPV-associated lesions. Furthermore, due to the considerable burden of HPV infections worldwide, it would take decades for preventive vaccines to affect the prevalence of cervical cancer. Thus, in order to speed up the control of cervical cancer and treat current infections, the continued development of therapeutic vaccines against HPV is critical. Therapeutic HPV vaccines can potentially eliminate pre-existing lesions and malignant tumors by generating cellular immunity against HPV-infected cells that express early viral proteins such as E6 and E7.

Objective: This review discusses the future directions of therapeutic HPV vaccine approaches for the treatment of established HPV-associated malignancies, with emphasis on current progress of HPV vaccine clinical trials.

Methods: Relevant literature is discussed.

Results/conclusion: Though their development has been challenging, many therapeutic HPV vaccines have been shown to induce HPV-specific antitumor immune responses in preclinical animal models and several promising strategies have been applied in clinical trials. With continued progress in the field of vaccine development, HPV therapeutic vaccines may provide a potentially promising approach for the control of lethal HPV-associated malignancies.

Citing Articles

Human papillomavirus type 16 and 18 viral clearance and progression to precancer among women aged 18-25 years enrolled in the Costa Rica HPV prophylactic vaccine trial (CVT).

Sierra M, Carvajal L, Dull P, Herrero R, Schussler J, Hildesheim A Vaccine. 2025; 50:126841.

PMID: 39961279 PMC: 11894763. DOI: 10.1016/j.vaccine.2025.126841.

DNA vaccines as promising immuno-therapeutics against cancer: a new insight.

Shariati A, Khezrpour A, Shariati F, Afkhami H, Yarahmadi A, Alavimanesh S Front Immunol. 2025; 15:1498431.

PMID: 39872522 PMC: 11769820. DOI: 10.3389/fimmu.2024.1498431.

Epidemiology, Molecular Pathogenesis, Immuno-Pathogenesis, Immune Escape Mechanisms and Vaccine Evaluation for HPV-Associated Carcinogenesis.

Jain M, Yadav D, Jarouliya U, Chavda V, Yadav A, Chaurasia B Pathogens. 2023; 12(12).

PMID: 38133265 PMC: 10745624. DOI: 10.3390/pathogens12121380.

A combined immunopeptidomics, proteomics, and cell surface proteomics approach to identify immunotherapy targets for diffuse intrinsic pontine glioma.

Pandey K, Wang S, Mifsud N, Faridi P, Davenport A, Webb A Front Oncol. 2023; 13:1192448.

PMID: 37637064 PMC: 10455951. DOI: 10.3389/fonc.2023.1192448.

Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects.

Khadela A, Shah Y, Mistry P, Bodiwala K, Cb A Technol Cancer Res Treat. 2023; 22:15330338221150559.

PMID: 36683526 PMC: 9893386. DOI: 10.1177/15330338221150559.

References

Tsen S, Paik A, Hung C, Wu T . Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines. 2007; 6(2):227-39. PMC: 3190226. DOI: 10.1586/14760584.6.2.227. View

Goldberg M, Maris C, Hipkiss E, Flies A, Zhen L, Tuder R . Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood. 2007; 110(1):186-92. PMC: 1896112. DOI: 10.1182/blood-2006-12-062422. View

Ferrara A, Nonn M, Sehr P, Schreckenberger C, Pawlita M, Durst M . Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol. 2003; 129(9):521-30. DOI: 10.1007/s00432-003-0463-5. View

Kim J, Hung C, Juang J, He L, Kim T, Armstrong D . Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther. 2004; 11(12):1011-8. DOI: 10.1038/sj.gt.3302252. View

Wang T, Ling M, Shih I, Pham T, Pai S, Lu Z . Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther. 2000; 7(9):726-33. DOI: 10.1038/sj.gt.3301160. View

Hallez S, Detremmerie O, Giannouli C, Thielemans K, Gajewski T, Burny A . Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer. 1999; 81(3):428-37. DOI: 10.1002/(sici)1097-0215(19990505)81:3<428::aid-ijc17>3.0.co;2-#. View

Daftarian P, Mansour M, Benoit A, Pohajdak B, Hoskin D, Brown R . Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine. 2006; 24(24):5235-44. DOI: 10.1016/j.vaccine.2006.03.079. View

Klencke B, Matijevic M, Urban R, Lathey J, Hedley M, Berry M . Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res. 2002; 8(5):1028-37. View

Rubinstein N, Alvarez M, Zwirner N, Toscano M, Ilarregui J, Bravo A . Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell. 2004; 5(3):241-51. DOI: 10.1016/s1535-6108(04)00024-8. View

10.

Sewell D, Douven D, Pan Z, Rodriguez A, Paterson Y . Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine. Arch Otolaryngol Head Neck Surg. 2004; 130(1):92-7. DOI: 10.1001/archotol.130.1.92. View

11.

Zwaveling S, Ferreira Mota S, Nouta J, Johnson M, Lipford G, Offringa R . Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol. 2002; 169(1):350-8. DOI: 10.4049/jimmunol.169.1.350. View

12.

Chang E, Chen C, Ji H, Wang T, Hung K, Lee B . Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer. 2000; 86(5):725-30. DOI: 10.1002/(sici)1097-0215(20000601)86:5<725::aid-ijc19>3.0.co;2-k. View

13.

Frazer I, Quinn M, Nicklin J, Tan J, Perrin L, Ng P . Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine. 2004; 23(2):172-81. DOI: 10.1016/j.vaccine.2004.05.013. View

14.

Smyth L, van Poelgeest M, Davidson E, Kwappenberg K, Burt D, Sehr P . Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res. 2004; 10(9):2954-61. DOI: 10.1158/1078-0432.ccr-03-0703. View

15.

Kang T, Lee J, Song C, Han H, Shin B, Pai S . Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res. 2007; 67(2):802-11. PMC: 3181129. DOI: 10.1158/0008-5472.CAN-06-2638. View

16.

Santin A, Bellone S, Gokden M, Cannon M, Parham G . Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med. 2002; 346(22):1752-3. DOI: 10.1056/NEJM200205303462219. View

17.

Kim M, Sin J . Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model. Immunology. 2005; 116(2):255-66. PMC: 1817814. DOI: 10.1111/j.1365-2567.2005.02219.x. View

18.

Lin C, Tsai Y, He L, Calizo R, Chou H, Chang T . A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. J Biomed Sci. 2006; 13(4):481-8. DOI: 10.1007/s11373-006-9086-6. View

19.

Bijker M, Melief C, Offringa R, van der Burg S . Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines. 2007; 6(4):591-603. DOI: 10.1586/14760584.6.4.591. View

20.

Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L . Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007; 13(7):828-35. PMC: 2135607. DOI: 10.1038/nm1609. View